- Home
- MUA vs FHTX Comparison
MUA vs FHTX Comparison
Compare MUA & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MUA | FHTX |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 517.6M | 419.9M |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MUA | FHTX |
|---|---|---|
| Price | $9.93 | $5.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | ★ 329.0K | 328.8K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,909,000.00 |
| Revenue This Year | N/A | $8.89 |
| Revenue Next Year | N/A | $20.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $9.92 | $3.27 |
| 52 Week High | $11.78 | $7.61 |
Technical Indicators
Market Signals| Indicator | MUA | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 30.93 | 44.58 |
| Support Level | N/A | $4.43 |
| Resistance Level | $10.87 | $5.93 |
| Average True Range (ATR) | 0.09 | 0.47 |
| MACD | 0.00 | -0.13 |
| Stochastic Oscillator | 4.44 | 1.62 |
Price Performance
Historical ComparisonAbout MUA Blackrock MuniAssets Fund Inc
Blackrock Muniassets Fund Inc is a closed-end fund. Its objective is to provide high current income exempt from U.S. federal income taxes by investing in a portfolio of medium- to lower-grade or unrated municipal obligations. The Fund invests more of its total assets in municipal bonds.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.